Interleukin 2– and Interferon Alpha Induced Natural Killer Cell Activity as a Marker of Progression in Hairy Cell Leukemia

References

• Golde D. W., Jacobs A. D., Glaspy J. A., Champlin R. E. Hairy-cell leukemia: biology and treatment. Semin, Hematol. 1986; 23: 3–9
   PubMed Web of Science ®Google Scholar
• Ruco L. P., Procopio A., Maccalini V., Calogero A., Uccini S., Annino L., Mandelli F., Baroni C. D. Severe deficiency of natural killer activity in the peripheral blood of patients with hairy cell leukemia. Blood 1983; 61: 1132–1137
   PubMed Web of Science ®Google Scholar
• Foa R., Lauria F., Lusso P., Raspadori D., Fierro M. T., Tazari P. L., Caudana L., Matera L. Phenotypic and functional characterization of the circulating NK compartment in hairy cell leukemia. Clin. Exp. Immunol. 1986; 64: 392–398
   PubMed Web of Science ®Google Scholar
• Ritz J. The role of natural killer cells in immune surveillance. New England J. Med 1989; 320: 1748–1749
   PubMed Web of Science ®Google Scholar
• Bigda J., Mysliwska J., Baran W., Zoltowska A., Hellmann A. Increase of NK cell-mediated cytotoxicity of hairy cell leukemia patients after splenectomy. Eur. J. Haematol. 1989; 63: 78–79
   Google Scholar
• Lotzova E., Ades E. W. Natural killer cells: definition, heterogeneity, lytic mechanism, functions and clinical application. Nat. Immun. Cell Growth Regui 1989; 7: 249–252
   Google Scholar
• Tokuda Y., Ebina N., Golub S. H. The inhibitory effect of human interferon alpha on the generation of lymphokine-activated killer activity. Cancer Immunol. Immu-nother. 1989; 30: 205–212
   PubMed Web of Science ®Google Scholar
• Bigda J. The possible mechanism of depression of NK cell cytotoxic activity in hairy cell leukemia. Hemalol. Reviews 1991; 5: 77–83
   Google Scholar
• Michalewicz R., Revel M. Interferons regulate in vitro differentiation of multilineage lympho-myeloid stem cells in hairy cell leukemia. Proc. Natl. Acad. Sci. USA 1987; 84: 2307–2311
   PubMed Web of Science ®Google Scholar
• Chilosi M., Semenzato G., Cetto G., Ambrosetti A., Fiore-Donati L., Perrona G., Berton G., Lestani M., Scarpa A., Agostini C., Trentin L., Zambello R., Masciarelli M., Dazzi F., Vinante F., Caligaris-Cappio F., Pizzolo G. Soluble interleukin-2 receptors in the sera of patients with hairy cell leukemia: relationship with the effect of recombinant alpha-interferon therapy on clinical parameters and natural killer in vitro activity. Blood 1987; 70: 1530–1535
   PubMed Web of Science ®Google Scholar
• Semenzato G., Pizzolo G., Agostini C., Abrosetti A., Zambello R., Trentin L., Luca M., Masciarelli M., Chilosi M., Vinante F., Perona G., Cetto G. Alpha-interferon activates the natural killer system in patients with hairy cell leukemia. Blood 1986; 68: 293–296
   PubMed Web of Science ®Google Scholar
• Demeter J., Paloczi K., Lehoczky D., Benczur M. Hairy cell leukemia: observations on natural killer activity in different clinical stages of the disease. Brit. J. Haematol. 1989; 71: 239–244
   PubMed Web of Science ®Google Scholar
• Hooper W. C., Barth R. F., Shah N. T. Lack of natural killer activity in hairy cell leukemia patients and partial restoration with interleukin 2. Cancer 1986; 57: 988–993
   PubMed Web of Science ®Google Scholar
• Demeter J., Benczur M. Hairy cells are not lysed by autologous LAK cells. Blut 1989; 58: 49–50
   PubMedGoogle Scholar
• Lahat N., Aghai S., Kotler A., Kinarty A., Sobel E., Gruener N., Froom P. Discordant effect of interferon on natural killer activity and tumor cell sensitivity to lysis in hairy cell leukemia. Blood 1988; 71: 1141–1143
   PubMed Web of Science ®Google Scholar
• Semenzato G., Trentin L., Zambello R., Agostini C., Chisesi T., Pizzolo G. Hairy cell sensitivity to the lysis in vitro. Role of the anti-CD3 antibody in generating a susceptibility to the lysis. Cancer Immunol. Immunother. 1989; 30: 254–256
   PubMed Web of Science ®Google Scholar
• Cordingley F. T., Hoffbrand A. V., Brenner M. K. Cytokine-induced enhancement of the susceptibility of hairy cell leukaemia lymphocytes to natural killer cell lysis. Brit. J. Haematol. 1988; 70: 37–41
   PubMed Web of Science ®Google Scholar
• Gemlo B. T., Palladino M. A., Jaffe H. S., Espevik T. P., Rayner A. A. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells. Cancer Res. 1988; 48: 5864–5867
   PubMed Web of Science ®Google Scholar
• Mier J. W., Vachino G., van der Meer J. V. M., Numerof R. P., Adams S., Cannon J. G., Bernheim H. A., Atkins M. B., Parkinson D. R., Dinarello C. A. Induction of circulating tumor necrosis factor (TNF alpha) as a mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients. J. Clin. Immunol. 1988; 8: 426–436
   PubMed Web of Science ®Google Scholar
• Drexler H. G. Which cells do respond during in vitro stimulation of B-CLL and HCL cultures?. Leukemia 1988; 2: 708–709
   PubMed Web of Science ®Google Scholar
• Barut B. A., Cochran M. K., O'Hara C., Anderson K. N. Response pattern of hairy cell leukemia to B-cell mitogens and growth factors. Blood 1990; 76: 2091–2097
   PubMed Web of Science ®Google Scholar
• Rubin L. A., Jay G., Nelson D. L. The released interleukin 2 receptor binds interleukin 2 efficiently. J. Immunol. 1986; 137: 3841–3844
   PubMed Web of Science ®Google Scholar